Results 1 to 10 of about 266,459 (207)
Quantitative Modeling of the Alternative Pathway of the Complement System. [PDF]
PLoS ONE, 2016 The complement system is an integral part of innate immunity that detects and eliminates invading pathogens through a cascade of reactions. The destructive effects of the complement activation on host cells are inhibited through versatile regulators that
Nehemiah Zewde +3 more
doaj +8 more sources
Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway
Frontiers in Immunology, 2021 The complement system is central to first-line defense against invading pathogens. However, excessive complement activation and/or the loss of complement regulation contributes to the development of autoimmune diseases, systemic inflammation, and ...
Jonathan Barratt +2 more
doaj +2 more sources
Looking back on the alternative complement pathway. [PDF]
Immunobiology, 2018 The alternative pathway of complement originated from the Properdin pathway originally described by the Pillemer laboratory in the 1950s. This work generated great controversy and it took several decades for a consensus on its components, its reaction sequence and its functions to emerge.
P. Lachmann
semanticscholar +3 more sources
Frontiers in Immunology, 2021 BackgroundThe SARS-CoV-2 infection triggers excessive immune response resulting in increased levels of pro-inflammatory cytokines, endothelial injury, and intravascular coagulopathy.
Federica Defendi +21 more
doaj +2 more sources
Dengue virus and the complement alternative pathway. [PDF]
FEBS Letters, 2020 Dengue disease is an inflammatory driven pathology and complement overactivation is linked to disease severity and vascular leakage. Additionally, dysregulation of complement alternative pathway (AP) components has been described, such as upregulation of
J. Carr +4 more
semanticscholar +4 more sources
Frontiers in Immunology, 2018 The complement system has moved into the focus of drug development efforts in the last decade, since its inappropriate or uncontrolled activation has been recognized in many diseases.
József Dobó +2 more
doaj +2 more sources
Alternative Complement Pathway Inhibition by Lampalizumab
Ophthalmology Science, 2023 Purpose: Lampalizumab, an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D (CFD), is designed to treat geographic atrophy (GA) secondary to age-related macular degeneration.
Rose Edmonds, MS +3 more
doaj +2 more sources
Diagnosis of complement alternative pathway disorders. [PDF]
Kidney International, 2016 Kidney diseases resulting from abnormal control of the complement alternative pathway include atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as atypical postinfectious glomerulonephritis. Although clinically diverse, they all result from loss of surface or fluid-phase complement control, caused by acquired
A. Angioi +8 more
semanticscholar +4 more sources
Haematologica, 2017 Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement ...
Xuan Yuan +8 more
doaj +2 more sources
Low‐molecular weight inhibitors of the alternative complement pathway
Immunological Reviews, 2022 Dysregulation of the alternative complement pathway predisposes individuals to a number of diseases. It can either be evoked by genetic alterations in or by stabilizing antibodies to important pathway components and typically leads to severe diseases ...
A. Schubart, S. Flohr, T. Junt, J. Eder
semanticscholar +1 more source